ONC
Beone MedicinesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ONC
Beone Medicines Ltd.
A Chinese developer of innovative, molecularly targeted and immuno-oncology drugs to treat cancer
Pharmaceutical
10/28/2010
02/03/2016
NASDAQ Stock Exchange
11,000
12-31
Depository Receipts (Ordinary Shares)
No. 30 Science Park Road, Zhong-Guan-Cun Life Science Park, Changping District, Beijing, PRC
Research, develop, produce and commercialize innovative drugs.
Beigene, Ltd.'s main business is research, development, production and commercialization of innovative drugs. The company's main products are Baiyueze, Baizean, Baihuize, Angavir, Belitor, Kailos, Savinco, Kaiser Bai, Pubexi (a biosimilar of Avaserelin), Baituowei (goserelin microspheres for injection), Tafina (dalafenib), Maginine (trametinib), Viquant (pazopanib), Fenito (everolimus), Zancoda (ceritinib). As of the end of the reporting period, the invention patents owned by the company and its holding subsidiaries include 64 invention patents in the United States, 67 invention patents in China, 30 invention patents in Japan, 15 invention patents in Europe and 135 invention patents in other countries or regions.
Company Financials
EPS
ONC has released its 2025 Q3 earnings. EPS was reported at 2.65, versus the expected 0.86, beating expectations. The chart below visualizes how ONC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ONC has released its 2025 Q3 earnings report, with revenue of 1.41B, reflecting a YoY change of 41.00%, and net profit of 124.84M, showing a YoY change of 202.88%. The Sankey diagram below clearly presents ONC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
